STALLERGENES-GREER
9.7.2021 10:02:12 CEST | Business Wire | Press release
Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), and Alyatec, a contract research organisation based in Strasbourg University Hospital (France), today announced that they have entered into a collaboration to advance precision medicine in AIT.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210709005081/en/
With this collaboration, Stallergenes Greer aims to strengthen its precision medicine-based approach and the management of patients with allergies by expanding its knowledge of allergy pathophysiology and endotypes, AIT mode of action and clinical validation.
This research collaboration brings together the longstanding expertise of Stallergenes Greer in AIT and Alyatec’s competencies in research and clinical services as well as its state-of-the-art technology, including a new generation environmental exposure chamber.
“We are excited about the collaboration with Alyatec which will support Stallergenes Greer’s ambition to advance the practice of allergology. With Alyatec and its team of distinguished key opinion leaders, Stallergenes Greer will continue to build on precision medicine and personalised healthcare to significantly improve patient disease outcomes ”, declared Amer Jaber, Executive VP Operations Europe and International and President of Stallergenes SAS.
“This collaboration is a remarkable opportunity for Alyatec to develop precision medicine in AIT. The field of allergology is the oldest form of precision medicine as patient phenotypes are directly related to specific results provided by skin tests. We are convinced that adapting immunotherapy to the phenotype of each patient, in other words finding the right immunotherapy for the right patient, is the future of AIT,” stated Professor Frédéric de Blay, Principal investigator and Medical expert of Alyatec.
ABOUT ALLERGEN IMMUNOTHERAPY
Allergies are the most prevalent and fastest growing chronic disease in the industrialised world, affecting over one billion people worldwide1 . Allergen immunotherapy is an allergy treatment designed to alter the natural course of respiratory allergies by treating the underlying cause of the disease. Allergen extracts are modifying disease by inducing tolerance in the immune system2,3 .
ABOUT STALLERGENES GREER
Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergy immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).
ABOUT ALYATEC
Alyatec is a contract research organisation based in Strasbourg University Hospital (France) which performs clinical studies related to respiratory allergies. Thanks to its specific knowledge and medical expertise Alyatec can evaluate the effect of solutions against asthma, rhinitis and conjunctivitis caused by environmental factors such as cat allergens, pollens and house dust mites. To perform these clinical trials, Alyatec has an environmental exposure chamber which enables the assessment of the mode of action of allergy treatment solutions in an innovative and efficient way. The company provides a full range of clinical services in the area of respiratory allergies with all the benefits related to the use of Alyatec’s allergen exposure unit.
1.World Health organisation, Ambient Air Pollution: Health Impacts
2.Global Atlas of Allergy, EAACI 2014
3.Halken 2017: EAACI guidelines on allergen immunotherapy: Prevention of allergy
View source version on businesswire.com: https://www.businesswire.com/news/home/20210709005081/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RecVue Launches First AI Native Agentic Revenue Operating System21.7.2026 15:03:00 CEST | Press release
New agentic architecture for RevOS runs enterprise revenue across the order-to-cash lifecycle and surfaces cross-system intelligence RecVue, the leader in billing and revenue management solutions, today announced the evolution of RecVue RevOS into the industry's first Agentic Revenue Operating System. In an architectural shift, the now-native agentic revenue management platform moves revenue operations beyond AI-assisted workflows to fully governed, autonomous execution with more than 50 purpose-built agents that work across contracts, invoices and payment data to predict risk, surface anomalies and escalate exceptions throughout the quote-to-cash lifecycle. Enterprise revenue operations have long suffered from a structural gap between billing systems that generate invoices and ERP systems that record transactions. Finance teams face tedious, manual reconciliation month after month, often resulting in delayed cash, billing errors that generate disputes, revenue leakage from ungoverned
Yubico Extends Passkeys Beyond Trusted Authentication to Verified Authorization with Launch of YubiKey 5.821.7.2026 15:00:00 CEST | Press release
YubiKey 5.8 extends hardware-backed assurance from authentication into emerging digital signature, wallet, payment and agentic approval workflows Yubico (NASDAQ STOCKHOLM: YUBICO), the pioneer of phishing-resistant authentication and creator of the original passkey, the YubiKey, today announced the general availability of its YubiKey 5.8 – marking an expansion of the role of the passkey from secure authentication to include verifiable, hardware-backed authorization. The new firmware delivers a foundation for secure enterprise workflows across identity wallets, document signing, and AI-driven approvals, while also providing developers with the critical capabilities needed to test, design and deploy these next-generation security features early. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721286409/en/ As generative and agentic AI mature to drive rapid, automated cyberattacks, traditional multi-factor authentication (MFA
Gurobi Publishes Inaugural State of Mathematical Optimization in Academia Report21.7.2026 15:00:00 CEST | Press release
Findings showcase how academics are leveraging optimization alongside GenAI tools in the classroom and in research today. Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the publication of its inaugural State of Mathematical Optimization in Academia Report. Based on surveys of over 1,180 faculty and students who actively use Gurobi, the report examines how optimization is being taught, used in research, and applied across academia today—as well as use cases that could benefit from a combination of generative AI (GenAI) with optimization. Gurobi’s research highlights the importance of making optimization education and tools accessible to students and instructors. “Mathematical optimization is powering some of the most effective decision-making across today’s enterprises, and the academic community is key to advancing its theory and practice,” said Duke Perrucci, CEO, Gurobi. “By exploring how students, researchers, and educators are teaching and
ExaGrid Announces a Record Bookings and Revenue Quarter21.7.2026 14:00:00 CEST | Press release
ExaGrid Achieves 22nd Consecutive Quarter of Free Cash Flow, EBITDA, and P&L Positive Operations ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most comprehensive security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that it had a record quarter of bookings and revenue in the second quarter ending June 30, 2026, with double-digit revenue growth over Q2 of 2025 and double-digit revenue growth for the first six months of 2026 over 2025. In addition, ExaGrid remained P&L, EBITDA, and free cash flow positive for the 22nd consecutive quarter. The company is 100% debt-free, demonstrating strong financial health as a company. ExaGrid added 207 new customers in Q2 2026, including 99 six- and seven-figure new customer deals in the quarter, with five of those over $1M each. Highlights of Q2 2026: Strong competitive win rate at over 80% for the quarter. Brought on 207 new customers. 99 six- and seven-figure n
Alpaca Launches German Equities Trading via Deutsche Börse Xetra21.7.2026 13:00:00 CEST | Press release
Broker partners can offer access to German equities through the Frankfurt Stock Exchange, one of the world’s largest trading venues Alpaca, a global leader in agent-first brokerage infrastructure, today announced that its broker partners can now offer trading in German equities through Deutsche Börse Xetra, providing access to one of Europe’s largest equity markets. The launch marks the first phase of Alpaca’s broader global equities initiative. In the coming months, Alpaca expects to roll out access to additional major international exchanges, including Hong Kong Stock Exchange, London Stock Exchange, Saudi Exchange, Euronext Paris, and Korea Exchange, with additional markets planned. Germany is the largest economy in Europe and the third largest in the world, behind the United States and China. Through Xetra, Alpaca’s broker partners can offer access to hundreds of German equities, including shares in companies such as SAP, Siemens, Allianz, BMW, Deutsche Bank, Adidas, and Bayer, acr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom